ODM-201new-generation androgen receptor inhibitor CAS# 1297538-32-9 |
- Calpain Inhibitor I, ALLN
Catalog No.:BCC1233
CAS No.:110044-82-1
- CA 074
Catalog No.:BCC1141
CAS No.:134448-10-5
- Cathepsin Inhibitor 1
Catalog No.:BCC4896
CAS No.:225120-65-0
- L 006235
Catalog No.:BCC2361
CAS No.:294623-49-7
- Balicatib
Catalog No.:BCC5139
CAS No.:354813-19-7
- MDL 28170
Catalog No.:BCC2352
CAS No.:88191-84-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1297538-32-9 | SDF | Download SDF |
| PubChem ID | 67171867 | Appearance | Powder |
| Formula | C19H19ClN6O2 | M.Wt | 398.85 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | BAY-1841788; Darolutamide | ||
| Solubility | DMSO : 100 mg/mL (250.72 mM; Need ultrasonic) | ||
| Chemical Name | N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide | ||
| SMILES | CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O | ||
| Standard InChIKey | BLIJXOOIHRSQRB-PXYINDEMSA-N | ||
| Standard InChI | InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | ODM-201 is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in AR-HEK293 cells.In Vitro:In competitive AR binding assays, the inhibition constant (Ki) values of ODM-201 are 11 nM. ODM-201and ORM-15341 suppresse androgen-induced cell proliferation more efficaciously than enzalutamide or ARN-509, IC50 values being 230 and 170 nM for ODM-201 and ORM-15341 vs. 410 and 420 nM for enzalutamide and ARN-509. ODM-201 has no effect on the viability of AR-negative cell lines tested, DU-145 prostate cancer cells and H1581 lung cancer cells confirming that the antiproliferative properties of ODM-201 and ORM-15341 are specific to AR-dependent PC cells[1].In Vivo:ODM-201 showes a significant antitumor activity with both doses, 50 mg/kg twice daily being more efficacious compared to castrated, untreated mice (p < 0.001) or enzalutamide (p = 0.0245), which also showes inhibition of tumor growth (p < 0.05) vs. castrated, untreated mice. Further, there is no sign of treatment-related toxicities; the body weights of mice treated with ODM-201 twice daily do not decrease significantly during the treatment[1]. References: | |||||
ODM-201 Dilution Calculator
ODM-201 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5072 mL | 12.536 mL | 25.0721 mL | 50.1442 mL | 62.6802 mL |
| 5 mM | 0.5014 mL | 2.5072 mL | 5.0144 mL | 10.0288 mL | 12.536 mL |
| 10 mM | 0.2507 mL | 1.2536 mL | 2.5072 mL | 5.0144 mL | 6.268 mL |
| 50 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.0029 mL | 1.2536 mL |
| 100 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.5014 mL | 0.6268 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ODM-201 is a new-generation inhibitor of androgen receptor with Ki value of 11 nM [1].
Androgen receptor is a type of nuclear receptor that is activated by androgen and functions as a DNA-binding transcription factor that regulates gene expression. Activation of androgen receptor (AR) is crucial for prostate cancer growth [1].
ODM-201 is a high-affinity and potent androgen receptor antagonist. In competitive AR binding assays, ODM-201 exhibited Ki value of 11 nM. In AR-HEK293 cells stably expressing full-length human AR (hAR) and an androgen-responsive luciferase reporter gene construct, ODM-201 and its major metabolite ORM-15341 inhibited AR-mediated transactivation with IC50 values of 26 nM and 38 nM. In human U2-OS osteosarcoma cells expressing wtAR or mutant AR(F876L), AR(W741L), or AR(T877A), ODM-201 and ORM-15341 also functioned as full antagonists. in AR overexpressing HS-HEK293 cells, ODM-201 inhibited the androgen-induced nuclear translocation of overexpressed AR. In the VCaP cell line with endogenous AR gene amplification and AR overexpression, ODM-201 inhibited androgen-induced cell proliferation with IC50 value of 230 nM.
In castrated male nude mice with subcutaneously injected VCaP cells, orally treatment with ODM-201 (50 mg/kg) once (qd) or twice daily (bid) for 37 days, ODM-201 showed a significant antitumor activity with both doses. There was no sign of treatment-related toxicities. In orthotopic VCaP tumor-bearing intact nude mice, ODM-201 (50 mg/kg, bid) significantly inhibited tumor growth but did not affect the testosterone levels in serum. ODM-201 couldn’t penetrate the blood-brain barrier [1].
Reference:
Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep, 2015, 5: 12007.
- Anemoside B4
Catalog No.:BCN1276
CAS No.:129741-57-7
- Anemoside A3
Catalog No.:BCN2328
CAS No.:129724-84-1
- 3-Hydroxylanost-9(11)-24-dien-26-oic acid
Catalog No.:BCN1586
CAS No.:129724-83-0
- 2',4'-Dihydroxy-3',6'-dimethoxychalcone
Catalog No.:BCN6158
CAS No.:129724-43-2
- Aripiprazole
Catalog No.:BCC5034
CAS No.:129722-12-9
- Dofequidar
Catalog No.:BCC4176
CAS No.:129716-58-1
- ZD 7114 hydrochloride
Catalog No.:BCC6852
CAS No.:129689-28-7
- 3,4-Dihydroxybisabola-1,10-diene
Catalog No.:BCN7326
CAS No.:129673-87-6
- 3-Hydroxybisabola-1,10-dien-9-one
Catalog No.:BCN7325
CAS No.:129673-86-5
- GR 82334
Catalog No.:BCC5802
CAS No.:129623-01-4
- Nevirapine
Catalog No.:BCC3820
CAS No.:129618-40-2
- Satraplatin
Catalog No.:BCC5356
CAS No.:129580-63-8
- MC 976
Catalog No.:BCC1734
CAS No.:129831-99-8
- Amicarbazone
Catalog No.:BCC5464
CAS No.:129909-90-6
- Dapoxetine HCl
Catalog No.:BCC5064
CAS No.:129938-20-1
- Iloperidone hydrochloride
Catalog No.:BCC4212
CAS No.:1299470-39-5
- Senecionine
Catalog No.:BCN2129
CAS No.:130-01-8
- 1,4-Naphthoquinone
Catalog No.:BCN8420
CAS No.:130-15-4
- Thioridazine HCl
Catalog No.:BCC3869
CAS No.:130-61-0
- Protopine
Catalog No.:BCN6165
CAS No.:130-86-9
- Quinine HCl
Catalog No.:BCN2262
CAS No.:130-89-2
- Quinine
Catalog No.:BCN2341
CAS No.:130-95-0
- I-BET151 (GSK1210151A)
Catalog No.:BCC4476
CAS No.:1300031-49-5
- GSK1324726A
Catalog No.:BCC4038
CAS No.:1300031-52-0
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.[Pubmed:26137992]
Sci Rep. 2015 Jul 3;5:12007.
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also castration-resistant prostate cancer (CRPC) is dependent on functional AR, and several mechanisms have been proposed to explain the addiction. Known causes of CRPC include gene amplification and overexpression as well as point mutations of AR. We report here the pharmacological profile of ODM-201, a novel AR inhibitor that showed significant antitumor activity and a favorable safety profile in phase 1/2 studies in men with CRPC. ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR. Importantly, ODM-201 also blocks the activity of the tested mutant ARs arising in response to antiandrogen therapies, including the F876L mutation that confers resistance to enzalutamide and ARN-509. In addition, ODM-201 reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model. In contrast to other antiandrogens, ODM-201 shows negligible brain penetrance and does not increase serum testosterone levels in mice. In conclusion, ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs. ODM-201 is currently in a phase 3 trial in CRPC.
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.[Pubmed:26313416]
Expert Rev Anticancer Ther. 2015;15(9):1007-17.
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.[Pubmed:26463318]
Eur Urol. 2016 May;69(5):834-40.
BACKGROUND: ODM-201 is a novel second-generation androgen receptor inhibitor for the treatment of metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate the pharmacokinetics of ODM-201 tablet products and preliminary long-term safety, tolerability, and antitumor activity of ODM-201 in chemotherapy-naive men with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Thirty patients were enrolled in this open-label phase 1 trial. Patients received a single 600-mg dose of ODM-201 in capsules with food and one 600-mg dose of ODM-201 tablet product (TabA or TabB) with food and in the fasted state in a random order. In the extension, patients received 600mg twice daily ODM-201 taken with food in capsules. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analyzed the pharmacokinetics of ODM-201 tablet formulations. Safety and tolerability were assessed until disease progression or an intolerable adverse event (AE). Antitumor activity was assessed by prostate-specific antigen (PSA) levels and imaging. RESULTS AND LIMITATIONS: The capsule:TabA ratio of area under the concentration-time curve from time zero to the last sample at 48h was 1.06 (90% confidence interval [CI], 0.91-1.24); the capsule:TabB ratio was 0.97 (90% CI, 0.82-1.14). At week 12, 25 of 30 patients (83%) had a PSA response (>/=50% reduction from baseline). Median time to radiographic progression was 66 wk (95% CI, 41-79). Most common AEs were fatigue (n=4 [13%]) and nausea (n=4 [13%]). CONCLUSIONS: The study showed that the tablet formulation of ODM-201 had similar pharmacokinetics compared with the capsule. Treatment with a 600-mg twice daily dose of ODM-201 provided anticancer activity and was well tolerated in men with chemotherapy-naive mCRPC. PATIENT SUMMARY: The findings of this study showed that ODM-201 is well tolerated and provided antitumor activity in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC) and that the 300-mg tablet formulation can be used in further clinical studies. A phase 3 trial with ODM-201 600mg twice daily in patients with non-mCRPC is ongoing.
